News coverage about Minerva Neurosciences (NASDAQ:NERV) has been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Minerva Neurosciences earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.1715310632978 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of Minerva Neurosciences (NERV) traded up $0.20 on Friday, reaching $6.25. The company’s stock had a trading volume of 383,022 shares, compared to its average volume of 201,688. The company has a market cap of $234.14, a price-to-earnings ratio of -5.58 and a beta of 1.53. Minerva Neurosciences has a 52-week low of $4.80 and a 52-week high of $11.90.
Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter. During the same quarter in the previous year, the company posted ($0.24) earnings per share. equities analysts predict that Minerva Neurosciences will post -1.28 earnings per share for the current year.
NERV has been the subject of a number of recent analyst reports. Zacks Investment Research cut Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Thursday, October 5th. ValuEngine lowered Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $13.94.
In other news, CFO Geoff Race sold 5,829 shares of the firm’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $5.79, for a total value of $33,749.91. Following the transaction, the chief financial officer now directly owns 197,698 shares in the company, valued at approximately $1,144,671.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 12,590 shares of company stock worth $73,073 over the last 90 days. 21.60% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Minerva Neurosciences (NERV) Share Price” was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2018/01/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-minerva-neurosciences-nerv-share-price.html.
About Minerva Neurosciences
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.